Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Nakamori M, Nakatani D, Sato T, Hasuike Y, Kon S, Saito T, Nakamura H, Takahashi MP, Hida E, Komaki H, Matsumura T, Takada H, Mochizuki H.
Nakamori M, et al. Among authors: hasuike y.
EClinicalMedicine. 2023 Dec 26;67:102390. doi: 10.1016/j.eclinm.2023.102390. eCollection 2024 Jan.
EClinicalMedicine. 2023.
PMID: 38314057
Free PMC article.